Semax

Semax is a synthetic heptapeptide analogue derived from the ACTH(4-7) sequence, studied in non-human models in relation to melanocortin receptor signaling, BDNF and NGF expression modulation, and neuroprotective pathway behavior. Scientific literature examines this compound in the context of CNS-related peptide signaling, neurotrophic factor upregulation, and dopaminergic pathway activity in controlled non-human research environments.

Research applications commonly explored in the literature include:

Melanocortin receptor signaling and ACTH-fragment analogue activity research

BDNF and NGF expression modulation in neurological research models

Dopaminergic and serotonergic pathway signaling investigation in non-human systems

Neuroprotective signaling pathway research in CNS-focused laboratory frameworks

Neuropeptide stability and metabolic resistance modeling relative to parent ACTH sequences

The lyophilized vial format allows researchers to evaluate compound stability, reconstitution characteristics, and handling parameters within controlled laboratory settings, supporting consistency across experimental preparation. Each Semax 30 mg vial from KÖLD is prepared and filled in the United States under sterile laboratory conditions. All batches are verified by independent third-party laboratories for purity, volume accuracy, and molecular identity.

1. What is Semax studied for in research settings?
Semax appears in scientific literature in relation to melanocortin receptor signaling, BDNF/NGF expression, and dopaminergic pathway activity. Research models investigate its behavior as an ACTH-derived neuropeptide analogue within CNS-focused signaling frameworks in non-human systems.

2. What is the structural classification of Semax?
Semax is a synthetic heptapeptide — a seven amino acid sequence — derived from the ACTH(4-7) proline-glycine-proline fragment with structural modifications designed to extend metabolic stability beyond the parent sequence. It is structurally and functionally distinct from steroids and growth hormones.

3. How does Semax relate to ACTH in research literature?
ACTH is an endogenous pituitary hormone. Semax was developed as a synthetic fragment analogue of a short ACTH subsequence (residues 4–7), modified to improve peptide half-life. Research examines how this truncated and stabilized structure interacts with melanocortin receptors and downstream neurotrophic signaling compared to the full ACTH sequence.

4. Is Semax approved for any use in humans or animals?
No. Semax is not approved for human or veterinary use in the jurisdictions in which KÖLD operates. All products sold by KÖLD are strictly for in vitro and non-human laboratory research purposes only.

5. How is purity and quality verified?
Each Semax 30 mg vial undergoes independent third-party laboratory testing to confirm molecular identity, purity, and volume accuracy prior to release.

Before Reconstitution

Store sealed vial in a freezer at -20°C (–4°F)

Keep away from light and humidity

After Reconstitution

Store at 4°C (39°F)

Use within 14 days

Avoid repeated freeze-thaw cycles

This compound is supplied as a lyophilized powder.
Use KÖLD Solution (sterile, lab-grade solvent) if your protocol requires reconstitution.
Reconstitute only when ready to begin your study.
For research use only. Not for human or animal use.
Not intended to diagnose, treat, cure, or prevent any disease.